Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025;21(5):29-41.
doi: 10.2174/011573403X345749250122092324.

The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis

Rubela Ray  1 , Arhum Mahmood  2 , Raheel Chaudhry  3 , Mohd Diya Masmoum  4 , Muhammad Talha  5 , Fahad I Siddiqui  6 , Imdad Ullah  7
Affiliations
Meta-Analysis

The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis

Rubela Ray et al. Curr Cardiol Rev. 2025.

Abstract

Introduction: Reducing the risk of atherosclerotic cardiovascular disease is the aim of lipid-lowering therapy (ASCVD). It is commonly acknowledged that low-density lipoprotein (LDL) is a major cause of ASCVD. Several online databases and search engines, such as Pub- Med and the Cochrane Library, were used to conduct a thorough search.

Methods: This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events. The RevMan 5.4 software was used to conduct the meta-analysis. This analysis included nine RCTs in total.

Results: Meta-analysis of the included studies showed that the levels of total cholesterol, LDL, and triglycerides were reduced after the use of PCSK9 inhibitors, and HDL levels were increased, which is good cholesterol. Most adverse cardiac events (MACE) were reduced after the use of PCSK9 inhibitors.

Conclusion: In conclusion, ezetimibe, a PCSK9 inhibitor added to statin therapy, further reduces MACE risk without affecting all-cause mortality, even though statins already significantly reduce major adverse cardiovascular events (MACE) and mortality.

Keywords: LDL cholesterol reduction; PCSK9 inhibitors; atherosclerotic cardiovascular disease; cardiovascular risk reduction.; ezetimibe; lipid-lowering agents; major adverse cardiovascular events; statin therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

References

    1. Borén J., Chapman M.J., Krauss R.M., Packard C.J., Bentzon J.F., Binder C.J., Daemen M.J., Demer L.L., Hegele R.A., Nicholls S.J., Nordestgaard B.G., Watts G.F., Bruckert E., Fazio S., Ference B.A., Graham I., Horton J.D., Landmesser U., Laufs U., Masana L., Pasterkamp G., Raal F.J., Ray K.K., Schunkert H., Taskinen M.R., van de Sluis B., Wiklund O., Tokgozoglu L., Catapano A.L., Ginsberg H.N. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2020;41(24):2313–2330. doi: 10.1093/eurheartj/ehz962. - DOI - PMC - PubMed
    1. Khan S.U., Yedlapati S.H., Lone A.N., Hao Q., Guyatt G., Delvaux N., Bekkering G.E.T., Vandvik P.O., Riaz I.B., Li S., Aertgeerts B., Rodondi N. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: A systematic review and network meta-analysis. BMJ. 2022;377:e069116. doi: 10.1136/bmj-2021-069116. - DOI - PubMed
    1. Hameed I., Shah S.A., Aijaz A., Mushahid H., Farhan S.H., Dada M., Khan A.B., Amjad R., Alvi F., Murtaza M., Zuberi Z., Hamza M. Comparative safety and efficacy of low/moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: An updated meta-analysis. Am. J. Cardiovasc. Drugs. 2024;24(3):419–431. doi: 10.1007/s40256-024-00642-8. - DOI - PubMed
    1. Roh E., Ko S.H., Kwon H.S., Kim N.H., Kim J.H., Kim C.S., Song K.H., Won J.C., Kim D.J., Choi S.H., Lim S., Cha B.Y. Prevalence and Management of Dyslipidemia in Korea: Korea National Health and Nutrition Examination Survey during 1998 to 2010. Diabetes Metab. J. 2013;37(6):433–449. doi: 10.4093/dmj.2013.37.6.433. - DOI - PMC - PubMed
    1. Ah Y.M., Jeong M., Choi H.D. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies. PLoS One. 2022;17(3):e0264437. doi: 10.1371/journal.pone.0264437. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources